Contineum Therapeutics (CTNM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.40
- Estimate
- -$0.45
- Surprise
- +10.8%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Contineum Therapeutics (CTNM) reported a narrower loss than forecast — diluted EPS of -$0.40 against the -$0.45 estimate (a 10.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CTNM Sell at 5.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +10.8% surprise compares with a +3.2% four-quarter average. Next scheduled report: 2026-10-29.
What argues against it
- Concentration risk — Pipeline: PIPE-791
- Quality below floor (1.6 < 4.0)
- Reward/Risk 1.2:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.19
- Price target
- $20.38
- Stop
- $15.99
- Upside to target
- +18.6%
- Reward-to-risk
- 1.2:1
Model outputs from TrendMatrix’s engine as of 2026-08-24 — shown for context, not personalized investment advice.
CTNM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $646.7M
- P/E (fwd)
- -9.6
- 52-week range
- $8.60–$17.35
- Off 52-week high
- 0.9%
- RSI (14)
- 60
- Volume vs avg
- 0.68×
- Score today
- 5.3/10